User:Pmmuab77/Anandamide

Lead
Anandamide is also being explored for its role in diabetic neuropathy/neuropathy as well as in reduction of inflammation associated with renal injury.

Article body
Research has suggested that Endocannabinoids disturb homeostasis in the body in several ways, either by encouraging hunger sensations and food intake and by shifting energy balance in the body towards energy storage. A resultant decrease in energy expenditure was also observed. [40]

Another study with rats expressed that reductions in AEA signaling through FAAH overexpression within the basolateral complex of amygdala (BLA) appeared to reliably reduce measurements of anxiety and overall levels of corticosterone, a primary glucocorticoid in animals like birds, rodents, reptiles and amphibians responsible for energy regulation, immune and stress responses. This is similar to the main glucocorticoid cortisol in humans. Reduction of AEA in the BLA has been shown to suppress fear behavior as well as promote fear extinction. This suggests possible involvement of AEA intervention in the future for the treatment of psychological disorders. However, further work in this area of study is needed to strengthen this belief, as reduced anandamide signaling is believed at this moment to involve CB1 receptors as well as GABAergic and glutamatergic interactions.[41]

Cortical glutamatergic transmission may be modulated by endocannabinoids during stress and fear habituation.[42] Glutamatergic interaction in the BLA believed to be responsible for changes in anxiety, appears to normalize stress-induced anxiety-like behavior. A current study indicated that infusion of the GluK1 receptor agonist, ATPA, into the BLA enhanced GABAergic neurotransmission, which is currently believed to have a large role in the reduction of anxiety symptoms.[43]

Additionally, the ECs along with AEA has been highlighted for its potential involvement in obesity development and harmful effects on lipid and glucose metabolism, which may contribute to insulin resistance and deficiency, both of which are a large risk factor for developing Type 2 Diabetes. Blockade of CB1 receptors was found significantly to improve lipid resistance and lipid profile in obese subjects, but also has potential to increase fat accumulation through increased food intake, favored lipogenesis and reduced energy expenditure. This may also affect distant systems like the pancreas, liver, adipose tissue and skeletal muscle, with inflammation and apoptosis in the case of the pancreas. CB1R inhibition with peripherally restricted antagonists/inverse agonists may aid in the treatment of diabetic neuropathy and neuropathy. CB2R agonists may also show promise for the treatment of of inflammation, which contributes to renal injury.[44]

AEA was associated with nonalcoholic fatty liver disease, or NAFLD, severity, presence of nonalcoholic steatohepatitis(NASH), and fibrosis. Data suggests AEA as a marker for cardiometabolic disease and NAFLD severity. NAFLD can progress to more severe diseases, like NASH, cirrhosis, and hepatocellular carcinoma.[45]